SCHEMBL6400630

SCHEMBL6400630

CC(C)(C)OC(=O)N(CO)CCCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.47
HDAC3 O15379 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
NCOR2 Q9Y618 1/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
ALOX5 P09917 1/20 0.44
POLB P06746 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
KMT2A Q03164 1/20 0.43
ADRA1A P35348 2/20 0.42
SLC6A3 Q01959 2/20 0.42
CHRM2 P08172 1/20 0.42
HTR1A P08908 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1844315 0.90 L3MBTL1 (0.46) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7983925 0.90 L3MBTL1 (0.46) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7983626 0.89 L3MBTL1 (0.48) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL1760498 0.86 SSTR4 (0.41) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7971622 0.86 MC5R (0.46) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL25046666 0.86 L3MBTL1 (0.45) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL26995518 0.86 L3MBTL1 (0.48) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL1799805 0.85 HDAC1 (0.51) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL4289433 0.85 L3MBTL1 (0.44) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL8583347 0.85 MAOA (0.47) L3MBTL1HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed
WO-2003024923-A1 SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 L3MBTL1 4162/4885HDAC3 434/4885HDAC1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.